T cell immunoglobulin-3 as a new therapeutic target for rheumatoid arthritis

Bibliography

• Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001;44:2746-9
   PubMed Web of Science ®Google Scholar
• Lajas C, Abasolo L, Bellajdel B, Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003;49:64-70
   PubMed Web of Science ®Google Scholar
• Dugowson CE, Koepsell TD, Voigt LF, Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987 – 1989. Arthritis Rheum 1991;34:1502-7
   PubMedGoogle Scholar
• Li X, Yuan FL, Lu WG, The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun 2010;397:131-5
   PubMed Web of Science ®Google Scholar
• Yuan FL, Li X, Lu WG, IL-33: a promising therapeutic target for rheumatoid arthritis? Expert Opin Ther Targets 2011;15:529-34
   PubMed Web of Science ®Google Scholar
• Monney L, Sabatos CA, Gaglia JL, Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002;415:536-41
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Kuchroo VK. TIM-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol 2011;350:1-15
   PubMed Web of Science ®Google Scholar
• Chae SC, Park YR, Shim SC, The polymorphisms of Th1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritis. Immunol Lett 2004;95:91-5
   PubMed Web of Science ®Google Scholar
• Xu J, Yang Y, Liu X, The -1541 C > T and +4259 G > T of TIM-3 polymorphisms are associated with rheumatoid arthritis susceptibility in a Chinese Hui population. Int J Immunogenet 2011;38:513-18
   PubMedGoogle Scholar
• Hastings WD, Anderson DE, Kassam N, TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 2009;39:2492-501
   PubMed Web of Science ®Google Scholar
• Seki M, Oomizu S, Sakata KM, Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 2008;127:78-88
   PubMed Web of Science ®Google Scholar
• Lee J, Oh JM, Hwang JW, Expression of human TIM-3 and its correlation with disease activity in rheumatoid arthritis. Scand J Rheumatol 2011;40:334-40
   PubMed Web of Science ®Google Scholar
• Lee J, Park EJ, Noh JW, Underexpression of TIM-3 and blunted galectin-9-induced apoptosis of CD4+ T cells in rheumatoid arthritis. Inflammation 2012;35:633-7
   PubMed Web of Science ®Google Scholar
• Khademi M, Illes Z, Gielen AW, T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol 2004;172:7169-76
   PubMed Web of Science ®Google Scholar
• Anderson DE. TIM-3 as a therapeutic target in human inflammatory diseases. Expert Opin Ther Targets 2007;11:1005-9
   PubMed Web of Science ®Google Scholar
• Sabatos CA, Chakravarti S, Cha E, Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003;4:1102-10
   PubMed Web of Science ®Google Scholar
• Fukushima A, Sumi T, Fukuda K, Antibodies to T-cell Ig and mucin domain-containing proteins (Tim)-1 and 3 suppress the induction and progression of murine allergic conjunctivitis. Biochem Biophys Res Commun 2007;353:211-16
   PubMed Web of Science ®Google Scholar
• Sanchez-Fueyo A, Tian J, Picarella D, Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003;4:1093-101
   PubMed Web of Science ®Google Scholar
• Jones RB, Ndhlovu LC, Barbour JD, Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008;205:2763-79
   PubMed Web of Science ®Google Scholar
• Boenisch O, D'Addio F, Watanabe T, TIM-3: a novel regulatory molecule of alloimmune activation. J Immunol 2010;185:5806-19
   PubMedGoogle Scholar
• Su EW, Lin JY, Kane LP. TIM-1 and TIM-3 proteins in immune regulation. Cytokine 2008;44:9-13
   PubMed Web of Science ®Google Scholar
• Anderson AC, Anderson DE, Bregoli L, Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007;318:1141-3
   PubMed Web of Science ®Google Scholar
• Kuchroo VK, Dardalhon V, Xiao S, New roles for TIM family members in immune regulation. Nat Rev Immunol 2008;8:577-80
   PubMedGoogle Scholar
• Zhu C, Anderson AC, Schubart A, The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6:1245-52
   PubMed Web of Science ®Google Scholar
• Anderson AC, Anderson DE. TIM-3 in autoimmunity. Curr Opin Immunol 2006;18:665-9
   PubMed Web of Science ®Google Scholar
• Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem 1997;272:6078-86
   PubMed Web of Science ®Google Scholar
• Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, The costimulatory role of TIM molecules. Immunol Rev 2009;229:259-70
   PubMed Web of Science ®Google Scholar
• Imaizumi T, Kumagai M, Sasaki N, Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol 2002;72:486-91
   PubMed Web of Science ®Google Scholar
• Sakai K, Kawata E, Ashihara E, Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. Eur J Immunol 2011;41:67-75
   PubMed Web of Science ®Google Scholar
• Veenstra RG, Taylor PA, Zhou Q, Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood 2012;120:682-90
   PubMed Web of Science ®Google Scholar
• Oomizu S, Arikawa T, Niki T, Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin Immunol 2012;143:51-8
   PubMedGoogle Scholar
• Pan HF, Zhang N, Li WX, TIM-3 as a new therapeutic target in systemic lupus erythematosus. Mol Biol Rep 2010;37:395-8
   PubMedGoogle Scholar
• Liu Y, Shu Q, Gao L, Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity. Clin Immunol 2010;137:288-95
   PubMed Web of Science ®Google Scholar
• Seki M, Sakata KM, Oomizu S, Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum 2007;56:3968-76
   PubMed Web of Science ®Google Scholar
• Arikawa T, Watanabe K, Seki M, Galectin-9 ameliorates immune complex-induced arthritis by regulating Fc gamma R expression on macrophages. Clin Immunol 2009;133:382-92
   PubMedGoogle Scholar